A Phase 2 interventional study of Pemetrexed and Erlotinib in Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy., sponsored by Eli Lilly and Company. Completed at 23 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-10-13.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a multicenter, randomized, Phase 2, open label, parallel trial to evaluate an effect of pemetrexed alone on nonsquamous non-small cell lung cancer (NSCLC) in a second-line setting (such as progression-free survival [PFS], disease control rate, best response rate, time to treatment failure [TTTF], overall survival [OS] and 1-year survival rates) compared to pemetrexed plus erlotinib combination.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group of participants with non-small cell lung cancer (NSCLC) of nonsquamous histology who were assigned to Pemetrexed arm
Drug: Pemetrexed
Group of participants with NSCLC of nonsquamous histology who were assigned to Pemetrexed + Erlotinib arm
Drug: Erlotinib · Drug: Pemetrexed
Group of participants with NSCLC of squamous histology who were assigned to Pemetrexed arm
Drug: Pemetrexed
Group of participants with NSCLC of squamous histology who were assigned to Pemetrexed + Erlotinib arm
Drug: Pemetrexed · Drug: Erlotinib
500 mg/m² intravenous (iv) over 10 minutes on the first day of each 21-day cycle until disease progression (PD) or unacceptable toxicity
Also known as: LY231514, Alimta
150 mg given orally (po), daily (QD), starting on the first day of the first cycle
Also known as: Tarceva
500 mg/m² iv over 10 minutes on the first day of each 21-day cycle until PD or unacceptable toxicity
Also known as: LY231514, Alimta
150 mg given po, QD, starting on the first day of the first cycle
Also known as: Tarceva
Progression Free Survival (PFS)
PFS per Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 criteria using computed tomography (CT) or magnetic resonance imaging (MRI) for objective determination of progressive disease (PD: ≤20% increase in sum of longest diameter of target lesion). For participants alive as of data cut-off date who did not have PD, PFS was censored at date of last CT/MRI. For participants who received subsequent systemic anticancer therapy (after study discontinuation) prior to PD or death, PFS censored at date of last CT/MRI prior to initiation of post discontinuation systemic anticancer therapy.
Time frame: Baseline to date of measured PD or death from any cause. Maximum follow-up was from baseline to 32.2 months
Percentage of Participants With Best Response of Stable Disease (SD), Partial Response (PR) or Complete Response (CR) (Disease Control Rate)
Per RECIST: CR: Disappearance of all target lesions; PR: Either a) ≤30% decrease in sum of longest diameter (LD) of target lesions or b) complete disappearance of target lesions, with persistence (but not worsening) of ≥1 nontarget lesions. In either case, no new lesions may have appeared. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as references the smallest sum LD. PD: ≤20% increase in sum of LD of target lesions. Disease Control Rate (%) = (SD+PR+CR)/number of participants in arm\*100.
Time frame: Baseline to measured PD. Maximum follow-up was from Baseline to 34 months
Percentage of Participants With Best Response of Complete Response (CR) or Partial Response (PR) (Response Rate)
CR: Disappearance of all tumor lesions; PR: Either a) at least a 30% decrease in sum of LD of target lesions or b) complete disappearance of target lesions, with persistence (but not worsening) ≥1 nontarget lesions. In either case, no new lesions may have appeared. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as references the smallest sum LD. PD: ≤20% increase in the sum of LD of target lesions. Response Rate (%) = (CR+PR)/number of participants in arm\*100.
Time frame: Baseline to measured progressive disease. Maximum follow-up was from Baseline to 34 months
Time to Treatment Failure (TTTF)
Defined as the time from randomization to death from any cause, first observation of PD, or study treatment discontinuation due to any reason other than "protocol complete" or "satisfactory response". For participants who discontinued due to "protocol complete" or "satisfactory response", or for participants not known to have discontinued as of the data cut-off date, TTTF was censored at the last contact date.
Time frame: Baseline to first date among death from any cause, PD, or study treatment discontinuation for any reason other than "protocol complete" or "satisfactory response". Maximum follow-up was from Baseline to 32.2 months
Overall Survival (OS)
OS time is the duration from randomization to the date of death from any cause. For each participant who was not known to have died as of the data inclusion cut-off date, OS was censored at the date of last contact.
Time frame: Baseline to date of death from any cause. Maximum follow-up was from Baseline to 42.6 months.
Percentage of Participants Surviving at 1 Year
Overall Survival (OS) rate at 1 year from the date of randomization was determined using the distribution of OS times and was estimated using the Kaplan-Meier method.
Time frame: Baseline to date of death from any cause up to 1 year
Number of Participants With Adverse Events (AEs)
Summaries of serious AEs (SAEs) and all other non-serious AEs are located in the Reported Adverse Event Module.
Time frame: Baseline up to 42.2 months
| Milestone | Pemetrexed (Nonsquamous) | Pemetrexed + Erlotinib (Nonsquamous) | Pemetrexed (Squamous) | Pemetrexed + Erlotinib (Squamous) |
|---|---|---|---|---|
| Started | 83 | 76 | 19 | 26 |
| Completed | 0 | 3 | 0 | 0 |
| Not completed | 83 | 73 | 19 | 26 |
| Withdrew: Adverse event | 4 | 10 | 0 | 3 |
| Withdrew: Death due to study disease | 6 | 4 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 |
| Withdrew: Entry criteria not met | 1 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 5 | 1 | 1 |
| Withdrew: Physician decision | 9 | 6 | 3 | 1 |
| Withdrew: Sponsor decision | 1 | 1 | 0 | 0 |
| Withdrew: Progressive disease | 58 | 43 | 13 | 18 |
| Withdrew: Death due to adverse event | 0 | 0 | 1 | 2 |
| Withdrew: Death, study drug related | 0 | 1 | 0 | 0 |
PFS per Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 criteria using computed tomography (CT) or magnetic resonance imaging (MRI) for objective determination of progressive disease (PD: ≤20% increase in sum of longest diameter of target lesion). For participants alive as of data cut-off date who did not have PD, PFS was censored at date of last CT/MRI. For participants who received subsequent systemic anticancer therapy (after study discontinuation) prior to PD or death, PFS censored at date of last CT/MRI prior to initiation of post discontinuation systemic anticancer therapy.
| months | Pemetrexed (Nonsquamous) | Pemetrexed + Erlotinib (Nonsquamous) |
|---|---|---|
| Progression Free Survival (PFS) | 2.9 (1.94 to 3.38) | 3.2 (2.86 to 4.70) |
Per RECIST: CR: Disappearance of all target lesions; PR: Either a) ≤30% decrease in sum of longest diameter (LD) of target lesions or b) complete disappearance of target lesions, with persistence (but not worsening) of ≥1 nontarget lesions. In either case, no new lesions may have appeared. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as references the smallest sum LD. PD: ≤20% increase in sum of LD of target lesions. Disease Control Rate (%) = (SD+PR+CR)/number of participants in arm\*100.
| percentage of participants | Pemetrexed (Nonsquamous) | Pemetrexed + Erlotinib (Nonsquamous) |
|---|---|---|
| Percentage of Participants With Best Response of Stable Disease (SD), Partial Response (PR) or Complete Response (CR) (Disease Control Rate) | 51.8 (40.6 to 62.9) | 55.3 (43.4 to 66.7) |
CR: Disappearance of all tumor lesions; PR: Either a) at least a 30% decrease in sum of LD of target lesions or b) complete disappearance of target lesions, with persistence (but not worsening) ≥1 nontarget lesions. In either case, no new lesions may have appeared. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as references the smallest sum LD. PD: ≤20% increase in the sum of LD of target lesions. Response Rate (%) = (CR+PR)/number of participants in arm\*100.
| percentage of participants | Pemetrexed (Nonsquamous) | Pemetrexed + Erlotinib (Nonsquamous) |
|---|---|---|
| Percentage of Participants With Best Response of Complete Response (CR) or Partial Response (PR) (Response Rate) | 10.8 (5.1 to 19.6) | 17.1 (9.4 to 27.5) |
Defined as the time from randomization to death from any cause, first observation of PD, or study treatment discontinuation due to any reason other than "protocol complete" or "satisfactory response". For participants who discontinued due to "protocol complete" or "satisfactory response", or for participants not known to have discontinued as of the data cut-off date, TTTF was censored at the last contact date.
| months | Pemetrexed (Nonsquamous) | Pemetrexed + Erlotinib (Nonsquamous) |
|---|---|---|
| Time to Treatment Failure (TTTF) | 2.4 (1.74 to 2.99) | 3.0 (2.23 to 4.07) |
OS time is the duration from randomization to the date of death from any cause. For each participant who was not known to have died as of the data inclusion cut-off date, OS was censored at the date of last contact.
| months | Pemetrexed (Nonsquamous) | Pemetrexed + Erlotinib (Nonsquamous) |
|---|---|---|
| Overall Survival (OS) | 7.8 (5.29 to 10.41) | 11.8 (8.18 to 16.66) |
Overall Survival (OS) rate at 1 year from the date of randomization was determined using the distribution of OS times and was estimated using the Kaplan-Meier method.
| Percentage participants with OS ≥1 year | Pemetrexed (Nonsquamous) | Pemetrexed + Erlotinib (Nonsquamous) |
|---|---|---|
| Percentage of Participants Surviving at 1 Year | 34.1 (23.82 to 44.56) | 49.4 (37.25 to 60.36) |
Summaries of serious AEs (SAEs) and all other non-serious AEs are located in the Reported Adverse Event Module.
| participants | Pemetrexed (Nonsquamous and Squamous) | Pemetrexed + Erlotinib (Nonsquamous and Squamous) |
|---|---|---|
| serious adverse events | 43 | 53 |
| other adverse events | 91 | 98 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemetrexed (Nonsquamous and Squamous) | — | 43/102 (42.2%) | 91/102 (89.2%) |
| Pemetrexed + Erlotinib (Nonsquamous and Squamous) | — | 53/102 (52%) | 98/102 (96.1%) |
| Event | Pemetrexed (Nonsquamous and Squamous) | Pemetrexed + Erlotinib (Nonsquamous and Squamous) |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 4/102 | 10/102 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/102 | 10/102 |
| General physical health deteriorationGeneral disorders | 2/102 | 9/102 |
| ThrombocytopeniaBlood and lymphatic system disorders | 3/102 | 7/102 |
| NeutropeniaBlood and lymphatic system disorders | 3/102 | 5/102 |
| PneumoniaInfections and infestations | 3/102 | 4/102 |
| LeukopeniaBlood and lymphatic system disorders | 1/102 | 3/102 |
| DiarrhoeaGastrointestinal disorders | 0/102 | 3/102 |
| BronchitisInfections and infestations | 1/102 | 3/102 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 3/102 | 1/102 |
| Event | Pemetrexed (Nonsquamous and Squamous) | Pemetrexed + Erlotinib (Nonsquamous and Squamous) |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 8/102 | 44/102 |
| RashSkin and subcutaneous tissue disorders | 9/102 | 43/102 |
| NauseaGastrointestinal disorders | 24/102 | 32/102 |
| Decreased appetiteMetabolism and nutrition disorders | 13/102 | 31/102 |
| LeukopeniaBlood and lymphatic system disorders | 9/102 | 29/102 |
| NeutropeniaBlood and lymphatic system disorders | 14/102 | 28/102 |
| Weight decreasedInvestigations | 20/102 | 27/102 |
| AnaemiaBlood and lymphatic system disorders | 22/102 | 26/102 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 25/102 | 18/102 |
| FatigueGeneral disorders | 19/102 | 22/102 |
| Age Continuous(years) | Pemetrexed (Nonsquamous) | Pemetrexed + Erlotinib (Nonsquamous) | Pemetrexed (Squamous) | Pemetrexed + Erlotinib (Squamous) | Total |
|---|---|---|---|---|---|
| Mean | 59.8 ± 10.25 | 63.5 ± 9.70 | 63.9 ± 9.33 | 66.1 ± 8.58 | 62.3 ± 9.96 |
| Sex: Female, Male(Participants) | Pemetrexed (Nonsquamous) | Pemetrexed + Erlotinib (Nonsquamous) | Pemetrexed (Squamous) | Pemetrexed + Erlotinib (Squamous) | Total |
|---|---|---|---|---|---|
| Female | 34 | 30 | 0 | 2 | 66 |
| Male | 49 | 46 | 19 | 24 | 138 |
| Race/Ethnicity, Customized(participants) | Pemetrexed (Nonsquamous) | Pemetrexed + Erlotinib (Nonsquamous) | Pemetrexed (Squamous) | Pemetrexed + Erlotinib (Squamous) | Total |
|---|---|---|---|---|---|
| Caucasian | 82 | 75 | 19 | 26 | 202 |
| African | 0 | 0 | 0 | 0 | 0 |
| Hispanic | 1 | 0 | 0 | 0 | 1 |
| Native American | 0 | 0 | 0 | 0 | 0 |
| East Asian | 0 | 0 | 0 | 0 | 0 |
| West Asian | 0 | 1 | 0 | 0 | 1 |
| Region of Enrollment(participants) | Pemetrexed (Nonsquamous) | Pemetrexed + Erlotinib (Nonsquamous) | Pemetrexed (Squamous) | Pemetrexed + Erlotinib (Squamous) | Total |
|---|---|---|---|---|---|
| Austria | 4 | 5 | 2 | 0 | 11 |
| Germany | 44 | 37 | 6 | 15 | 102 |
| Spain | 18 | 9 | 7 | 7 | 41 |
| Hungary | 12 | 14 | 4 | 4 | 34 |
| Sweden | 5 | 11 | 0 | 0 | 16 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | Pemetrexed (Nonsquamous) | Pemetrexed + Erlotinib (Nonsquamous) | Pemetrexed (Squamous) | Pemetrexed + Erlotinib (Squamous) | Total |
|---|---|---|---|---|---|
| Status 0 | 33 | 33 | 7 | 9 | 82 |
| Status 1 | 39 | 33 | 7 | 13 | 92 |
| Status 2 | 11 | 9 | 5 | 4 | 29 |
| Unknown | 0 | 1 | 0 | 0 | 1 |
| Basis for Diagnosis(participants) | Pemetrexed (Nonsquamous) | Pemetrexed + Erlotinib (Nonsquamous) | Pemetrexed (Squamous) | Pemetrexed + Erlotinib (Squamous) | Total |
|---|---|---|---|---|---|
| Histopathological | 64 | 61 | 18 | 22 | 165 |
| Cytological | 19 | 15 | 1 | 4 | 39 |
| Initial Pathological Diagnosis(participants) | Pemetrexed (Nonsquamous) | Pemetrexed + Erlotinib (Nonsquamous) | Pemetrexed (Squamous) | Pemetrexed + Erlotinib (Squamous) | Total |
|---|---|---|---|---|---|
| Adenocarcinoma of the lung | 70 | 61 | 0 | 0 | 131 |
| Mixed cell (squamous/adenocarcinoma) | 1 | 1 | 0 | 0 | 2 |
| Large cell lung carcinoma | 6 | 9 | 0 | 0 | 15 |
| Bronchioalveolar carcinoma | 4 | 1 | 0 | 0 | 5 |
| Squamous cell carcinoma of the lung | 0 | 0 | 19 | 26 | 45 |
| Unknown | 2 | 4 | 0 | 0 | 6 |
| Stage of Disease at Study Entry(participants) | Pemetrexed (Nonsquamous) | Pemetrexed + Erlotinib (Nonsquamous) | Pemetrexed (Squamous) | Pemetrexed + Erlotinib (Squamous) | Total |
|---|---|---|---|---|---|
| Stage I | 0 | 0 | 0 | 0 | 0 |
| Stage II | 0 | 0 | 0 | 0 | 0 |
| Stage IIIA | 3 | 1 | 2 | 0 | 6 |
| Stage IIIB | 10 | 11 | 4 | 5 | 30 |
| Stage IV | 70 | 64 | 13 | 21 | 168 |
2 further baseline measures are reported on the registry.
The record gives a start of Mar 2007, a primary completion of Jul 2010 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2011, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pemetrexed